GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XORTX Therapeutics Inc (NAS:XRTX) » Definitions » Forward PE Ratio
中文

XORTX Therapeutics (XORTX Therapeutics) Forward PE Ratio : 0.00 (As of Apr. 24, 2024)


View and export this data going back to 2018. Start your Free Trial

What is XORTX Therapeutics Forward PE Ratio?

XORTX Therapeutics's Forward PE Ratio for today is 0.00.

XORTX Therapeutics's PE Ratio without NRI for today is 0.00.

XORTX Therapeutics's PE Ratio for today is 0.00.


XORTX Therapeutics Forward PE Ratio Historical Data

The historical data trend for XORTX Therapeutics's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XORTX Therapeutics Forward PE Ratio Chart

XORTX Therapeutics Annual Data
Trend 2021-12 2022-02
Forward PE Ratio
1.28 0.91

XORTX Therapeutics Quarterly Data
2021-12
Forward PE Ratio 1.28

Competitive Comparison of XORTX Therapeutics's Forward PE Ratio

For the Biotechnology subindustry, XORTX Therapeutics's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XORTX Therapeutics's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XORTX Therapeutics's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where XORTX Therapeutics's Forward PE Ratio falls into.



XORTX Therapeutics Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


XORTX Therapeutics  (NAS:XRTX) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


XORTX Therapeutics Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of XORTX Therapeutics's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


XORTX Therapeutics (XORTX Therapeutics) Business Description

Traded in Other Exchanges
Address
3710 - 33rd Street NW, Calgary, AB, CAN, T2L 2M1
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.